Achillion to Present at the Three Upcoming Healthcare Conferences

Tue Nov 26, 2013 4:05pm EST

* Reuters is not responsible for the content in this press release.

NEW HAVEN, Conn., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:

  • Deutsche Bank 2013 BioFEST on Tuesday, December 3, 2013 at 10:10 a.m. ET at the Four Seasons Hotel Boston in Boston, MA;
     
  • The 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 12:30 p.m. ET at The New York Palace Hotel in New York, NY; and
     
  • Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11, 2013 at 1:35 p.m. ET at the Crowne Plaza Times Square in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's discovery, clinical development, and commercial teams have advanced multiple novel product candidates with proven mechanisms of action into studies and toward the market. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 752-5510
         gschulman@achillion.com
         
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com